Arcagy/ Gineco Group

This large, late-stage trial is testing whether adding the immunotherapy drug dostarlimab to standard chemotherapy works better than chemotherapy alone for women with advanced or recurrent endometrial cancer that has a specific genetic marker (MMR deficient). The main goal is to …

This study is testing if adding a new drug called relatlimab to an existing immunotherapy (nivolumab) works better for locally advanced cervical cancer. About 77 patients will receive the two-drug combination or nivolumab alone for six weeks before starting standard chemoradiatio…